title: In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.
abstract: Butylthio[2.2.2] (LY297802 / NNC11-1053) is a mixed muscarinic cholinergic receptor agonist/antagonist that produces antinociception in mice and rats. As such, butylthio[2.2.2] may have therapeutic utility in the treatment of pain. Butylthio[2.2.2] was fully efficacious in the mouse grid shock, writhing, tail-flick and hot plate tests with ED50 values ranging from 1.5 to 12.2 mg/kg after oral administration. In contrast, the ED50 values for morphine ranged from 7.3 to 72 mg/kg after oral administration. Scopolamine was a competitive antagonist of the antinociceptive effects of butylthio[2.2.2]. Butylthio[2.2.2] did not produce either salivation or tremor at therapeutic doses; rather, there was a 50- to >100-fold separation between therapeutic doses and doses which produced side-effects. Butylthio[2.2.2] had high affinity for muscarinic receptors, but little if any affinity for other neurotransmitter receptors or uptake sites. In isolated tissues, butylthio[2.2.2] was an agonist with high affinity at M1 receptors in rabbit vas deferens, an antagonist at M2 receptors in guinea pig atria as well as an antagonist at M3 receptors in guinea pig urinary bladder. Although it has been suggested that M1 receptors mediate the antinociceptive effects of muscarinic agonists, M1 efficacy is not a requirement for antinociception, and, in vivo, the antinociceptive effects of muscarinic agonists are blocked by the intrathecal administration of pertussis toxin, indicating the involvement of m2 or m4 receptors. Since butylthio[2.2.2] is an M2 antagonist, antinociception is therefore most likely mediated by m4 receptors. Butylthio[2.2.2] is currently undergoing clinical development as a novel analgesic.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
authors.forename: H E
authors.initials: HE
authors.lastname: Shannon
authors.forename: D E
authors.initials: DE
authors.lastname: Womer
authors.forename: F P
authors.initials: FP
authors.lastname: Bymaster
authors.forename: D O
authors.initials: DO
authors.lastname: Calligaro
authors.forename: N C
authors.initials: NC
authors.lastname: DeLapp
authors.forename: C H
authors.initials: CH
authors.lastname: Mitch
authors.forename: J S
authors.initials: JS
authors.lastname: Ward
authors.forename: C A
authors.initials: CA
authors.lastname: Whitesitt
authors.forename: M D
authors.initials: MD
authors.lastname: Swedberg
authors.forename: M J
authors.initials: MJ
authors.lastname: Sheardown
authors.forename: A
authors.initials: A
authors.lastname: Fink-Jensen
authors.forename: P H
authors.initials: PH
authors.lastname: Olesen
authors.forename: K
authors.initials: K
authors.lastname: Rimvall
authors.forename: P
authors.initials: P
authors.lastname: Sauerberg
mesh_terms: D000284:Administration, Oral; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology*; D000818:Animals; D006168:Guinea Pigs; D051379:Mice; D018721:Muscarinic Agonists / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D013830:Thiadiazoles / Q000494:pharmacology*
chemical_list: D018712:Analgesics, Non-Narcotic; D018721:Muscarinic Agonists; D013830:Thiadiazoles; C101714:LY 297802